Lanzul S

Lansoprazole, the active ingredient in Lanzul S, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal disorders in adults. GNH USA supplies Lanzul S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for conditions involving excess gastric acid production. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by lowering stomach acidity. - Duodenal ulcer: promotes healing of ulcer lesions through sustained acid suppression. - Helicobacter pylori eradication regimens: enhances antibiotic effectiveness by creating a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Nausea: occasional feeling of queasiness, typically mild. - Abdominal pain: discomfort in the stomach area, usually transient.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: kidney inflammation that may cause reduced urine output. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention.

Before initiating therapy, consider the following safety measures. - Assess renal and hepatic function: dose adjustment may be needed in impairment. - Evaluate for CYP2C19 polymorphisms: altered metabolism can affect drug levels. - Monitor long‑term use: prolonged therapy may increase risk of bone fractures. - Review concomitant medications: potential for reduced absorption of drugs requiring acidic pH. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption leading to therapeutic failure. - Atazanavir: markedly decreased antiviral exposure, compromising HIV treatment.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Methotrexate: elevated serum levels may occur, especially at high doses. - Digoxin: modest increase in plasma concentration, warranting dose review.